Foreign Clinical Trials: FDA Oversight To Include More Training, Data Collection
Executive Summary
Changes to FDA's policy for monitoring foreign clinical trials appear imminent after the Department of Health and Human Services Inspector General recommended the agency increase its oversight of data gathered outside the U.S
You may also be interested in...
Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves
FDA and EMA need more time working together before they can rely on each other’s Good Clinical Practice inspection findings, a recent joint report concludes.
Practice Makes Good: FDA, EMA Focus On CROs As GCP Info Sharing Improves
FDA and EMA need more time working together before they can rely on each other’s Good Clinical Practice inspection findings, a recent joint report concludes.
Clinical Trials Face More FDA Scrutiny; DoJ Settlements Focus On Data Use
FDA is ratcheting up enforcement of clinical trial sites, conducting more inspections during the course of pivotal studies and issuing more warning letters to investigators.